HC Wainwright Issues Positive Estimate for LXEO Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at HC Wainwright boosted their Q1 2025 earnings estimates for Lexeo Therapeutics in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.78) per share for the quarter, up from their previous estimate of ($0.93). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

A number of other research firms also recently commented on LXEO. Leerink Partners cut their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday. Chardan Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada lowered their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.80.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $4.11 on Friday. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50. The business has a 50-day moving average price of $4.07 and a 200 day moving average price of $6.63. The company has a market capitalization of $135.90 million, a P/E ratio of -1.30 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Allostery Investments LP acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics in the 4th quarter worth $46,000. BNP Paribas Financial Markets grew its stake in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Lexeo Therapeutics during the 4th quarter worth $69,000. Finally, SG Americas Securities LLC acquired a new position in Lexeo Therapeutics during the 4th quarter valued at about $72,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.